Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

Melanoma Research

Volumn 24, Issue 5, 2014, Pages 504-508

  Bowyer, Samantha E ^a   Rao, Aparna D ^c   Lyle, Megan ^e   Sandhu, Shahneen ^c   Long, Georgina V ^e,f   McArthur, Grant A ^c,d   Raleigh, Jeanette M ^c   Hicks, Rodney J ^c,d   Millward, Michael ^a,b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MELANOMA INSTITUTE AUSTRALIA   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

BRAF; K601E; L597; MEK inhibition; Melanoma; Metastatic; Trametinib

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; TRAMETINIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAF K601E GENE; BRAF L597 GENE; CLINICAL ARTICLE; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GENE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; MALE; METABOLISM; METASTATIC MELANOMA; NAUSEA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RASH; BIOPSY; CHEMISTRY; GENETICS; MELANOMA; METASTASIS; MIDDLE AGED; MUTATION; PHOSPHORYLATION; RETROSPECTIVE STUDY; SCINTISCANNING; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BIOPSY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PHOSPHORYLATION; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84926131772     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000099     Document Type: Article

References (15)

1. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:1239-1246.
2. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012;18:3242-3249.
3. Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF, Long GV. BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer 2013;49:1073-1079.
4. Amanuel B, Grieu F, Kular J, Millward M, Iacopetta B. Incidence of BRAF p. Val600Glu and p. Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology 2012;44:357-359.
5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
6. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet 2012;380:358-365.
7. McArthur G, Hauschild A, Robert C, Larkin J, Haanen JB, Ribas A, et al. Efficacy of vemurafenib in BRAF V600K mutation-positive melanoma disease: results from the phase 3 clinical study BRIM-3. Pigment Cell Melanoma Res 2012;25:871.
8. Lovly C, Pao W, Sosman J. Mycancergenome.org 2013. Available at: http://www.mycancergenome.org/content/disease/melanoma/braf/190. [Accessed 13 June 2013].
9. Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, et al. BRAF (L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2012;2:791-797.
10. Sullivan RJ, Flaherty KT. BRAF in melanoma: pathogenesis, diagnosis, inhibition, and resistance. J Skin Cancer 2011;2011:423239.
11. Bahadoran P, Allegra M, Le Duff F, Long-Mira E, Hofman P, Giacchero D, et al. Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. J Clin Oncol 2013;31:e324-e326.
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwart LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
13. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-114.
14. McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, et al. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 2012;30:1628-1634.
15. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31:482-489.